Can enasidenib cure leukemia?

Enasidenib (Enasidenib) is a drug used to treat certain types of acute myeloid leukemia (AML). It is an IDH2 inhibitor that can be effective in AML patients carrying IDH2 gene mutations. Each patient's situation is unique and treatment results will vary from person to person. As a drug, the efficacy of ensidipine is affected by many factors, including the severity of the condition, individual characteristics, and other possible health problems.

Currently, the treatment of acute myeloid leukemia requires a combination of multiple methods, including chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc. Ensidipine can be used as one of the treatments to help control the disease and prolong the survival of patients. However, it does not cure leukemia alone. Ensidipine is not suitable for all types of acute myeloid leukemia. It is mainly suitable for AML patients with specific genetic mutations, such as IDH2 mutations including R140Q, R172S and R172K. Therefore, before using ensidipine, corresponding genetic testing is required to determine whether the patient is suitable for treatment with this drug.

Encidipine research medicine is not currently on the market in China, so it cannot be included in medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic ensidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*30 tablets produced by a Laos pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to the exchange rate). Its pharmaceutical ingredients are basically the same as those of the original drugs sold abroad.